8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 18, 2008

Shire Limited

________________________________________________________________________________

(Exact name of registrant as specified in its charter)

Jersey

________________________________________________________________________________

(State or other jurisdiction of incorporation)

0-29630	98-0484822
(Commission File Number)	(IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,

Hampshire RG24 8EP England

________________________________________________________________________________

(Address of principal executive offices)	(Zip code)
Registrant's telephone number, including area code	44 1256 894 000

________________________________________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

[  ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.f13e-4(c))

Item 8.01.  Other Events

Shire Limited has issued the press release attached hereto as Exhibit 99.01 which is incorporated by reference herein.

Item 9.01.  Financial Statements and Exhibits

 (d)  Exhibits.  The following exhibit is filed herewith:

99.01        Press Release dated June 19, 2008

99.02        Press Release dated June 18, 2008

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant  has duly caused  this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE LIMITED
By:	/s/ A C Russell
Name:Angus Russell
Title:Chief Executive Officer

Dated: June 19, 2008

EXHIBIT INDEX
Number	Description
99.01	Press Release dated June 19, 2008

99.02 Press Release dated June 18, 2008

EX-99.1

EXHIBIT 99.01

HampshireInternationalBusinessPark Chineham  Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com
Press Release

Director/PDMR Shareholding

Basingstoke, UK and Philadelphia, US – June 19, 2008 – Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that on June 18, 2008, upon Mr Angus Russell becoming the Chief Executive Officer of the Company, the following awards under the Shire Portfolio Share Plan (the "Plan") were granted to Mr Russell. The awards will bring Mr Russell’s long term incentive awards in line with the stated policy for the Chief Executive Officer disclosed in the Company’s Remuneration Report.

A consistent methodology has been used to calculate the number of shares subject to this award, in line with all awards granted previously to Persons Discharging Managerial Responsibilities under the Plan (i.e. using the average share price in the previous financial year which, in 2007, was £11.55).

Awards of Stock Settled Appreciation Rights ("SARs") under Part A of the Plan

Type of Security	No. of Ordinary Shares	Exercise Price
Ordinary Share	123,547	£8.13

SARs will normally vest after three years, subject to performance targets being satisfied. Once vested, SARs will be capable of exercise for a period of two years. No consideration was paid for the grant of the SARs.

Performance Share Awards ("PSP Awards") under Part B of the Plan

Type of Security	No. of Ordinary Shares	Market value
Ordinary Share	96,410	£8.13

The PSP awards will normally vest after three years, subject to performance targets being satisfied. No consideration was paid for the grant of PSP awards.

Following this transaction, Mr. Russell holds options over 554,760 Ordinary Shares (of which options over 552,418 Ordinary Shares have vested) and awards over 881,580 Ordinary Shares (of which all are still to vest).

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.

T May

Company Secretary

Registered in England 5492592  Registered Office as above

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 484 595 8252

Notes to editors

SHIRE LIMITED

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.  Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com

Registered in England 5492592  Registered Office as above

EX-99.2

EXHIBIT 99.02

HampshireInternationalBusinessPark Chineham  Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com
Press Release

Notification of major interests in shares

Basingstoke, UK and Philadelphia, US – June 18, 2008 – Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Shire Limited

2. Reason for the notification	State Yes/No
An acquisition or disposal of voting rights	Yes
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An event changing the breakdown of voting rights
Other (please specify):  New Exemption DTR 5.1.3 (4) & DTR 5.1.5 (1)	Yes

3. Full name of person(s) subject to the notification obligation:	The Goldman Sachs Group Inc
4. Full name of shareholder(s) (if different from 3.):	Goldman, Sachs & Co., Goldman Sachs Financial Markets, L.L.C. Goldman Sachs Execution and Clearing, L.P
5. Date of the transaction (and date on which the threshold is crossed or reached if different):	16 June 2008
6. Date on which issuer notified:	18 June 2008
7. Threshold(s) that is/are crossed or reached:	Below 3%
8. Notified details:

1

A: Voting rights attached to shares

Class/type of shares  if possible using the ISIN CODE	Situation previous to the Triggering transaction		Resulting situation after the triggering transaction
	Number of Shares	Number of Voting Rights	Number of shares	Number of voting rights		% of voting rights
			Direct	Direct	Indirect	Direct	Indirect
GB00B0KQX869 US82481R1068	115,000 17,114,532 (5,704,844 ADRs)	0.021% 3.059%

B: Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument Expiration date Exercise/Conversion Period/ Date Number of voting rights that may be acquired if  the instrument is exercised/converted % of voting rights

Total (A+B)
Number of voting rights	% of voting rights
	Below 3%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

We hereby notify you that as at close of business on 16 June 2008, The Goldman Sachs Group, Inc., of 85 Broad Street, New York, NY 10004, USA, no longer has a notifiable interest in shares.

Proxy Voting:

10. Name of the proxy holder:	N/A
11. Number of voting rights proxy holder will cease to hold:	N/A
12. Date on which proxy holder will cease to hold voting rights:	N/A

13. Additional information:	General Email Contact: shareholderdisclosures@gs.com
14. Contact name:	Sean Rogers/Alan Cox
15. Contact telephone number:	0207-552-9205 / 0207-774 -8774

Contact at Shire Limited: Tony Guthrie, Deputy Company Secretary, 01256 894746

2

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 484 595 8252
Media	Jessica Mann (Rest of the World)	+44 1256 894 280
	Matthew Cabrey (North America)	+1 484 595 8248
	Jessica Cotrone (North America)	+1 617 613 4640

Notes to editors

SHIRE LIMITED

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.  Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.

3